litlas
Log inCreate account

Joaquín Martínez‐López

Active 2000–2025

Also published as
Joaquin Martinez Lopez · Joaquin Martinez-Lopez · Joaquín Martínez-López
242
Papers
19,834
Citations
67
h-index
211
i10-index

Citations

Citations per year for Joaquín Martínez‐López1979: 1 citations1993: 1 citations2001: 1 citations2002: 1 citations2003: 4 citations2004: 3 citations2005: 1 citations2006: 6 citations2007: 8 citations2008: 14 citations2009: 26 citations2010: 22 citations2011: 39 citations2012: 41 citations2013: 62 citations2014: 76 citations2015: 82 citations2016: 84 citations2017: 92 citations2018: 80 citations2019: 439 citations2020: 531 citations2021: 821 citations2022: 864 citations2023: 773 citations2024: 1,691 citations2025: 969 citations2026: 17 citations1980–1992: no citations, so these years are not shown1994–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,053 citing papers, 21.9% of this breakdownSpain: 678 citing papers, 7.2% of this breakdownChina: 624 citing papers, 6.7% of this breakdownGermany: 599 citing papers, 6.4% of this breakdownItaly: 576 citing papers, 6.1% of this breakdownUnited Kingdom: 511 citing papers, 5.5% of this breakdownFrance: 496 citing papers, 5.3% of this breakdownNetherlands: 333 citing papers, 3.6% of this breakdownCanada: 279 citing papers, 3% of this breakdownAustralia: 269 citing papers, 2.9% of this breakdownSwitzerland: 217 citing papers, 2.3% of this breakdownGreece: 200 citing papers, 2.1% of this breakdown
0%21.9%Other 27%

Institutions

Fields

  • Medicine81.6%
  • Biochemistry, Genetics and Molecular Biology10.2%
  • Immunology and Microbiology6.1%
  • Computer Science0.4%
  • Engineering0.3%
  • Agricultural and Biological Sciences0.3%
  • Other1.1%

Topics

  • Multiple Myeloma Research and Treatments12.6%
  • CAR-T cell therapy research9.1%
  • Protein Degradation and Inhibitors6.2%
  • Lymphoma Diagnosis and Treatment3.3%
  • Peptidase Inhibition and Analysis3%
  • Immune Cell Function and Interaction2.9%
  • Other62.9%

Coauthors

All papers

Open in search
  1. Teclistamab in Relapsed or Refractory Multiple Myeloma

    Authors: Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesús F. San Miguel, Albert Oriol, Ajay K. Nooka, Thomas G. Martin, Laura Rosiñol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, María‐Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Surbhi Sidana, Michel Delforge, Lixia Pei, Danielle Trancucci, Raluca Verona, Suzette Girgis, Shun Xin Wang Lin, Yunsi Olyslager, Mindy Jaffe, Clarissa Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani - New England Journal of Medicine 2022 cited by 1,114

  2. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    Authors: Jesús F. San Miguel, Binod Dhakal, Kwee Yong, Andrew Spencer, Sébastien Anguille, María‐Victoria Mateos, Carlos Fernández de Larrea, Joaquín Martínez‐López, Philippe Moreau, Cyrille Touzeau, Xavier Leleu, Irit Avivi, Michèle Cavo, Tadao Ishida, Seok Jin Kim, Wilfried Roeloffzen, Niels W.C.J. van de Donk, Dominik Dytfeld, Surbhi Sidana, Luciano J. Costa, Albert Oriol, Rakesh Popat, Abdullah Khan, Yaël C. Cohen, P. Joy Ho, James E. Griffin, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Jordan M. Schecter, Carolyn C. Jackson, Kaitlyn Connors, Katherine Li, Enrique Zudaire, Diana Chen, Jane Gilbert, Tzu‐Min Yeh, Sarah Nagle, Erika Florendo, Lida Pacaud, Nitin Patel, Simon J. Harrison, Hermann Einsele - New England Journal of Medicine 2023 cited by 733

  3. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

    Authors: Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf, Nizar J. Bahlis, H. Miles Prince, Rubén Niesvizky, Paula Rodríguez‐Otero, Joaquín Martínez‐López, Guenther Koehne, Cyrille Touzeau, Yogesh Jethava, Hang Quach, Julien Depaus, Hisayuki Yokoyama, Afshin Eli Gabayan, Don A. Stevens, Ajay K. Nooka, Salomon Manier, Noopur Raje, Shinsuke Iida, Marc S. Raab, Emma Searle, Eric Leip, Sharon T. Sullivan, Umberto Conte, Mohamed Elmeliegy, Akos Czibere, Andrea Viqueira, Mohamad Mohty - Nature Medicine 2023 cited by 564

  4. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

    Authors: Nathan Fowler, Michael Dickinson, Martin Dreyling, Joaquín Martínez‐López, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chávez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, José Antonio Pérez‐Simón, Andy I. Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés J.M. Ferreri, Takanori Teshima, Piers Patten, Joseph P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thiéblemont - Nature Medicine 2021 cited by 527

  5. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    Authors: Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian W. Flinn, Werner Rabitsch, Yok‐Lam Kwong, Marie José Kersten, Monique C. Minnema, Harald Holte, Esther Hian Li Chan, Joaquín Martínez‐López, Antonia Müller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David A. Bond, Charalambos Andreadis, Peter A. McSweeney, Mohamed A. Kharfan‐Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jäger, Peter Borchmann, Jason R. Westin - New England Journal of Medicine 2021 cited by 520

  6. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

    Authors: Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, Carmelo Carlo‐Stella, Fritz Offner, Anna Sureda, Gilles Salles, Joaquín Martínez‐López, Michael Crump, Denise Thomas, Peter N. Morcos, Cristiano Ferlini, Ann-Marie E Bröske, Anton Belousov, Marina Bacac, Natalie Dimier, David Carlile, Linda Lundberg, David Pérez-Callejo, Pablo Umaña, Tom Moore, Maja Weisser, Michael Dickinson - Journal of Clinical Oncology 2021 cited by 413

  7. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

    Authors: Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martınez, Chang‐Ki Min, Luděk Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Thomas G. Martin, Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kim Kihyun, Gracia Martınez, Min Chang‐Ki, Luděk Pour, Xavier Leleu, Albert Oriol, Koh Youngil, Kenshi Suzuki, Tom Martin, Hang Quach, Andrew Lim, Helen Crowther, Hanlon Sia, Cyrille Hulin, Mohamad Mohty, Gábor Mikala, Zsolt Nagy, Marta Reinoso Segura, Laura Rosiñol, Münci Yağcı, Mehmet Turgut, Mamta Garg, Gurdeep Parmar, Brad Augustson, Nelson Castro, Edvan de Queiroz Crusoé, Tomáš Pika, Sosana Delimpasi, Kenichi Ishizawa, Anup George, Т. С. Константинова, Javier de la Rubia, Kim Sung-Hyun, Ângelo Maiolino, Tony Reiman, Richard LeBlanc, Shigeki Ito, Junji Tanaka, А. С. Лучинин, I. V. Kryuchkova, Joaquín Martínez‐López, Jesse Shustik, Lionel Karlin, Anargyros Symeonidis, Miklós Egyed, Mario Petrini, Michèle Cavo, Michihiro Uchiyama, Hilary Blacklock, Mutlu Arat, James E. Griffin, Hannah Hunter, Tonda Buck, Αchilles Anagnostopoulos, Κωνσταντίνος Κωνσταντόπουλος, Tamás Masszi, Sara Bringhen, Barbara Gamberi, Yawara Kawano, Kim Jin Seok, Hakan Özdoğu, Fahir Özkalemkaş - The Lancet 2021 cited by 380

  8. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Authors: Juan Flores‐Montero, Luzalba Sanoja-Flores, Bruno Paiva, Noemí Puig, Omar García-Sánchez, Sebastian Böttcher, Vincent H. J. van der Velden, J.J. Pérez-Morán, María‐Belén Vídriales, Ramón García‐Sánz, Cristina Jiménez, Marcos González, Joaquín Martínez‐López, Alba Corral-Mateos, G-E Grigore, Rafael Fluxá, Robéria Mendonça de Pontes, Joana Caetano, Łukasz Sędek, MC del Cañizo, Joan Bladé, J-J Lahuerta, C. Aguilar, Abelardo Bárez, Aránzazu García‐Mateo, Jorge Labrador, Pilar Leóz, Carmen Aguilera-Sanz, Jesús F. San Miguel, MV Mateos, Brian G.M. Durie, Jacques J. M. van Dongen, A Orfao - Leukemia 2017 cited by 657

  9. Overcoming tumor resistance mechanisms in CAR-NK cell therapy

    Authors: Antonio Valeri, Almudena García-Ortiz, Eva Castellano, Laura Córdoba, Elena Maroto-Martín, Jessica Encinas, Alejandra Leivas, Paula Rı́o, Joaquín Martínez‐López - Frontiers in Immunology 2022 cited by 88

  10. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

    Authors: Susanne Saußele, Johan Richter, Joëlle Guilhot, Franz Gruber, Henrik Hjorth-Hansen, António Almeida, Jeroen J. W. M. Janssen, Jiřı́ Mayer, Perttu Koskenvesa, Panayiotis Panayiotidis, Ulla Olsson‐Strömberg, Joaquín Martínez‐López, Philippe Rousselot, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Kateřina Machová Poláková, Martin C. Müller, Satu Mustjoki, Marc Berger, Alice Fabarius, Wolf‐Karsten Hofmann, Andreas Hochhaus, Markus Pfirrmann, François‐Xavier Mahon, Gert J. Ossenkoppele, Maria Pagoni, Stina Söderlund, Martine Escoffre‐Barbe, Gabriel Étienne, Jolanta Dengler, Françoise Huguet, Nikolas von Bubnoff, Hana Klamová, Edgar Faber, François Guilhot, Kourosh Lotfi, Delphine Réa, Tim H. Brümmendorf, G.E. de Greef, Leif Stenke, Franck E. Nicolini, Laurence Legros, Andreas Burchert, J Voglová, Aude Charbonnier, Emmanuel Gyan, Volker Kunzmann, Peter E. Westerweel - The Lancet Oncology 2018 cited by 611

  11. Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

    Authors: Francesca Gay, Wilfried Roeloffzen, Meletios Α. Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Roberto Mina, Albert Oriol Rocafiguera, Eirini Katodritou, Ka Lung Wu, Paula Rodríguez‐Otero, Roman Hájek, Elisabetta Antonioli, Mark van Duin, Mattia D’Agostino, Joaquín Martínez‐López, Elena M. van Leeuwen-Segarceanu, Paola Tacchetti, Niels W.C.J. van de Donk, Katja Weisel, Luděk Pour, Jakub Radocha, Angelo Belotti, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Pieter Sonneveld, Mario Boccadoro, Annemiek Broijl - Blood 2023 cited by 99

  12. The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression

    Authors: Almudena García-Ortiz, Yaiza Rodríguez‐García, Jessica Encinas, Elena Maroto-Martín, Eva Castellano, Joaquı́n Teixidó, Joaquín Martínez‐López - Cancers 2021 cited by 225

  13. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma

    Authors: Alejandra Leivas, Antonio Valeri, Laura Córdoba, Almudena García-Ortiz, Alejandra Ortiz-Ruiz, Laura Sánchez-Vega, Osvaldo Graña‐Castro, Lucía Fernández, Gonzalo Carreño‐Tarragona, Manuel Pérez‐Martínez, Diego Megı́as, María Liz Paciello, José María Sánchez‐Pina, Antonio Pérez‐Martínez, Dean A. Lee, Daniel J. Powell, Paula Rı́o, Joaquín Martínez‐López - Blood Cancer Journal 2021 cited by 138

  14. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

    Authors: Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C. Lee, James E. Hoffman, Attaya Suvannasankha, Jeffrey A. Zonder, Mansi Shah, Suzanne Lentzsch, Rachid Baz, Joseph Maly, Swathi Namburi, Matthew J. Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca Silbermann, Chang‐Ki Min, Marie‐Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquín Martínez‐López, Kaniel Cassady, Michelle DeVeaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, George D. Yancopoulos, L. Andres Sirulnik, Karen Rodriguez Lorenc, Glenn S. Kroog, Yariv Houvras, Madhav V. Dhodapkar - Journal of Clinical Oncology 2024 cited by 135

  15. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).

    Authors: Niels W.C.J. van de Donk, Philippe Moreau, Alfred L. Garfall, Manisha Bhutani, Albert Oriol, Ajay K. Nooka, Thomas G. Martin, Laura Rosiñol, María‐Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Amrita Krishnan, Michel Delforge, Danielle Trancucci, Raluca Verona, Tara Stephenson, Katherine Chastain, Surbhi Sidana - Journal of Clinical Oncology 2023 cited by 65

  16. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Authors: Bruno Paiva, Noemí Puig, María‐Teresa Cedena, Laura Rosiñol, Lourdes Cordón, María‐Belén Vídriales, Leire Burgos, Juan Flores‐Montero, Luzalba Sanoja-Flores, Lucía López‐Anglada, Roberto Maldonado, Javier de la Cruz, Norma C. Gutiérrez, Marı́a José Calasanz, María-Luisa Martín-Ramos, Ramón García‐Sánz, Joaquín Martínez‐López, Albert Oriol, María‐Jesús Blanchard, Rafael Ríos, Jesús Martín, Rafael Martínez-Martinez, Anna Sureda, Miguel-Teodoro Hernandez, Javier de la Rubia, Isabel Krsnik, José M. Moraleda, Luis Palomera, Joan Bargay, Jacques J. M. van Dongen, Alberto Órfão, María‐Victoria Mateos, Joan Bladé, Jesús F. San Miguel, Juan José Lahuerta, on behalf of the GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group - Journal of Clinical Oncology 2019 cited by 276

  17. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

    Authors: Paul G. Richardson, Suzanne Trudel, Rakesh Popat, María‐Victoria Mateos, Annette Juul Vangsted, Karthik Ramasamy, Joaquín Martínez‐López, Hang Quach, Robert Z. Orlowski, Mario Arnao, Sagar Lonial, Chatchada Karanes, Charlotte Pawlyn, Kihyun Kım, Albert Oriol, Jesús G. Berdeja, Paula Rodríguez‐Otero, Ignacio Casas-Avilés, Alessia Spirlì, Jennifer Poon, Shaoyi Li, Jing Gong, Lilly Wong, Manisha Lamba, Daniel W. Pierce, Michael Amatangelo, Teresa Peluso, Paulo Maciag, Jessica Katz, Michael Pourdehnad, Nizar J. Bahlis - New England Journal of Medicine 2023 cited by 85

  18. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Authors: Juan‐José Garcés, María‐Teresa Cedena, Noemí Puig, Leire Burgos, José J. Pérez, Lourdes Cordón, Juan Flores‐Montero, Luzalba Sanoja-Flores, Marı́a José Calasanz, Albert Ortiol, María‐Jesús Blanchard, Rafael Ríos, Jesús Martín, Rafael Martínez-Martinez, Joan Bargay, Anna Sureda, Javier de la Rubia, Miguel-Teodoro Hernandez, Paula Rodríguez‐Otero, Javier de la Cruz, Alberto Órfão, María‐Victoria Mateos, Joaquín Martínez‐López, Juan José Lahuerta, Laura Rosiñol, Joan Bladé, Jesús F. San Miguel, Bruno Paiva - Journal of Clinical Oncology 2022 cited by 114

  19. A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2.

    Authors: Sean Nolan, Marissa Vignali, Mark Klinger, Jennifer N. Dines, Ian M. Kaplan, Emily Svejnoha, Tracy Craft, Katie Boland, Mitch Pesesky, Rachel Gittelman, Thomas M. Snyder, Christopher J. Gooley, Simona Semprini, Claudio Cerchione, Massimiliano Mazza, Ottavia M. Delmonte, Kerry Dobbs, Gonzalo Carreño‐Tarragona, Santiago Barrio, Vittorio Sambri, Giovanni Martinelli, Jason D. Goldman, James R. Heath, Luigi D. Notarangelo, Jonathan M. Carlson, Joaquín Martínez‐López, Harlan Robins - 2020 cited by 166

  20. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

    Authors: Martin Dreyling, Nathan Fowler, Michael Dickinson, Joaquín Martínez‐López, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chávez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, José Antonio Pérez‐Simón, Andy I. Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés J.M. Ferreri, Takanori Teshima, Piers Patten, Joseph P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Inès Paule, Aiesha Zia, Rakesh Awasthi, Xia Han, Davide Germano, Darragh O’Donovan, Roberto Ramos, Harald J. Maier, Aisha Masood, Catherine Thiéblemont, Stephen J. Schuster - Blood 2024 cited by 93

  21. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Authors: Jesús F. San Miguel, Katja Weisel, Philippe Moreau, Martha Q. Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrían Alegre, Christine Chen, Michèle Cavo, Laurent Garderet, Valentina Ivanova, Joaquín Martínez‐López, Andrew R. Belch, Antonio Palumbo, Stephen Schey, Pieter Sonneveld, Xin Yu, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Meletios Α. Dimopoulos - The Lancet Oncology 2013 cited by 799

  22. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Authors: Cristina Pérez, Cirino Botta, Aintzane Zabaleta, Noemí Puig, María‐Teresa Cedena, Ibai Goicoechea, Daniel Alameda, Edurne San José‐Eneriz, Juana Merino, Paula Rodríguez‐Otero, Catarina Maia, Diego Alignani, Patricia Maiso, Irene Manrique, David Lara‐Astiaso, Amaia Vilas‐Zornoza, Sarai Sarvide, Caterina Riillo, Marco Rossi, Laura Rosiñol, Albert Oriol, María‐Jesús Blanchard, Rafael Ríos, Anna Sureda, Jesús Martín, Rafael Martínez, Joan Bargay, Javier de la Rubia, Miguel-Teodoro Hernandez, Joaquín Martínez‐López, Alberto Órfão, Xabier Agirre, Felipe Prósper, María‐Victoria Mateos, Juan José Lahuerta, Joan Bladé, Jesús F. San Miguel, Bruno Paiva - Blood 2020 cited by 154

  23. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.

    Authors: Alfred L. Garfall, Ajay K. Nooka, Niels W.C.J. van de Donk, Philippe Moreau, Manisha Bhutani, Albert Oriol, Thomas G Martin, Laura Rosiñol, María‐Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Amrita Krishnan, Michel Delforge, Lin Huang, Deeksha Vishwamitra, Tara Stephenson, Katherine Chastain, Surbhi Sidana - Journal of Clinical Oncology 2024 cited by 77

  24. Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma

    Authors: Alba Rodríguez-García, Andrés Arroyo, Roberto García-Vicente, María Luz Morales, Rubén Gómez-Gordo, Pablo Justo, Clara Cuéllar, José María Sánchez‐Pina, Nieves López‐Muñoz, Rafael Alonso, Noemí Puig, María‐Victoria Mateos, Rosa Ayala, Dulcenombre Gómez‐Garré, Joaquín Martínez‐López, María Linares - Clinical Cancer Research 2023 cited by 59